research Supplementary Material for: Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
Search
for
Sort by
Research
480-510 / 1000+ resultsresearch P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research Carbobenzoxy-capped Phe-Lys(BODIPY TMR-X-acyloxymethyl ketone(QSY7)
Near-infrared probes can safely and effectively image cysteine protease activity for disease diagnosis.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
research Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
The document concludes that side effects from Smoothened inhibitor drugs for skin cancer are reversible and can be managed with a team approach to maintain quality of life.
research Janus Kinase Inhibitors in the Treatment of Alopecia Areata
JAK inhibitors, like baricitinib, are effective and safe for treating alopecia areata.
research A Case of Cicatricial Alopecia Associated with Erlotinib
Erlotinib can cause hair loss as a side effect.
research 증례 : Gefitinib에 의해 유발된 반흔성 탈모증
Gefitinib can cause rare scarring hair loss.
research Unusual progression of renal cell carcinoma with carcinomatosis peritoneii and Krukenberg tumour and alopecia with sunitinib therapy in young female
A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Alopecia areata: Ritlecitinib generates substantial re-growth of scalp hair
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
research Inhibiting Janus kinases to treat alopecia areata
JAK inhibitors might help treat alopecia areata.
research Direct reprogramming of human fibroblasts into hair-inducing dermal papilla cell-like cells by a single small molecule
Peficitinib can turn human fibroblasts into cells that help grow hair.
research Vorasidenib-Induced Trichomegaly and Hypertrichosis: a New Side Effect in a Patient with Diffuse Astrocytoma
Vorasidenib can cause unusual hair growth.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
research Janus kinase inhibitors for alopecia areata
JAK inhibitors offer new hope for treating severe alopecia areata.
research P64 Efficacy of baricitinib in patients with different degrees of severe alopecia areata: 52-week results from BRAVE-AA1 and BRAVE-AA2
Baricitinib was effective in treating severe and very severe alopecia areata after 52 weeks.
research Acneiform eruptions caused by an epidermal growth factor receptor-tyrosine kinase inhibitor ZD 1839
ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.
research Efficacy and safety of JAK inhibitors in treating lichen planopilaris or frontal fibrosing alopecia
JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
research Efficacy and Safety of Switching from Baricitinib to Ritlecitinib in Severe Alopecia Areata
Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.
research Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata
research JAK inhibition in the treatment of alopecia areata – a promising new dawn?
JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
research SYSTEMATIC REVIEW OF ORAL JANUS KINASE INHIBITORS IN ALOPECIA AREATA: INSIGHTS FROM 2020 TO 2025 STUDIES
Oral JAK inhibitors effectively treat alopecia areata and are generally well-tolerated.
research Ruxolitinib for the treatment of severe alopecia areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research LB1007 Systemic treatment with a KLK5 inhibitor shows efficacy in a murine model of Netherton syndrome
A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.
research Refractory/relapse thrombocytopenia in a patient with Evans' syndrome successfully treated with zanubrutinib
A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
research Severe scarring alopecia associated with combinational use of ficlatuzumab and gefitinib: a clinical and immunohistochemistry study
Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.